Continuation Study for Latozinemab

Inclusion Criteria:

• Written informed consent must be obtained and documented (from the participant or,where jurisdictions allow it, from their legal decision maker).

• Has successfully completed participation in their parent latozinemab study.

• Female participants must be nonpregnant and nonlactating.

• Male participants must agree to acceptable contraception use.

Exclusion Criteria:

• Known history of severe allergic, anaphylactic, or other hypersensitivity reactionsto chimeric, human, or humanized antibodies or fusion proteins.

• Clinically significant heart disease, liver disease or kidney disease. History orevidence of clinically significant brain disease other than FTD.